# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce lung cancer and metastasis

### Lung Bone-Specific Metastasis

- describe lung cancer types and symptoms
- discuss genetic factors and mutations
- classify lung cancers by histological type
- describe non-small-cell and small-cell lung carcinoma
- discuss prognosis and metastasis

## BRIEF SUMMARY OF THE INVENTION

- identify role of MAF in lung cancer metastasis
- associate c-MAF with bone metastasis
- describe method for diagnosing metastasis
- outline method for designing customized therapy
- describe method for predicting clinical outcome
- relate to use of c-MAF inhibitory agent
- describe various kits for predicting bone metastasis

## DETAILED DESCRIPTION OF THE INVENTION

- introduce c-MAF gene and protein overexpression in lung cancer metastasis
- describe method for diagnosis and prognosis of metastasis using c-MAF expression levels
- define terms and concepts related to metastasis and diagnosis
- describe methods for quantifying c-MAF gene expression levels
- define functionally equivalent variant of c-MAF protein
- describe methods for quantifying c-MAF protein expression level
- outline steps for comparing c-MAF gene expression levels
- determine reference sample and control sample
- define increased expression levels and positive diagnosis for metastasis
- describe osteolytic bone metastasis and tendency to develop metastasis
- define agent for avoiding or preventing bone degradation and c-MAF inhibitory agent
- define key terms
- explain Src and COX-2 inhibitors
- describe clinical outcomes and prognosis
- define treatment and sample analysis
- explain gene expression and chromosomal analysis
- define key terms
- describe method for designing customized therapy
- detail second method of the invention
- explain treatment options for lung cancer
- describe systemic treatments
- detail specific treatments, including Alpharadin and mTor inhibitors
- describe Src kinase inhibitors
- list COX-2 inhibitors
- describe use of COX-2 inhibitors to prevent or inhibit metastasis
- list treatment agents for avoiding and/or preventing bone degradation
- describe parathyroid hormone and parathyroid like hormone inhibitors
- describe strontium ranelate
- describe estrogen receptor modulators
- describe calcitonin, bisphosphonates, and cathepsin K inhibitors
- describe DKK-1, dual MET and VEGFR2, and RANKL inhibitors
- provide examples of RANKL inhibitors
- specify RANKL inhibitors
- specify embodiments
- outline third method of invention
- define agents for avoiding or preventing bone degradation
- illustrate examples of agents
- describe RANKL inhibitors
- describe dual MET and VEGFR2 inhibitors
- describe mTor inhibitors
- provide examples of mTor inhibitors
- describe use of mTor inhibitors in treatment
- describe Src kinase inhibitors
- describe COX-2 inhibitors
- describe Radium 223 therapy
- describe bisphosphonates
- describe combined treatments
- describe method of diagnosis or prognosis of metastasis in lung cancer
- describe determining amplification of c-MAF gene
- define amplification of a gene
- describe method for diagnosing metastasis in lung cancer
- explain gene copy number and its measurement
- detail method of prognosis of metastasis in lung cancer
- describe translocation of c-MAF gene and its measurement
- outline method of prognosis of clinical outcome in lung cancer
- summarize methods for determining amplification and translocation of c-MAF gene
- explain correlation with control sample or reference sample
- describe various probes and labels used in the methods
- outline different embodiments of the invention

### Therapeutic Methods of the Invention

- define therapeutic methods for treating bone metastasis
- describe use of c-MAF inhibitory agents for treating bone metastasis
- outline method for preventing bone metastasis in lung cancer patients
- introduce antisense oligonucleotides as c-MAF inhibitory agents
- describe design and function of antisense oligonucleotides
- discuss modifications to antisense oligonucleotides for improved stability and hybridization
- introduce siRNA as c-MAF inhibitory agents
- describe design and function of siRNA
- introduce DNA enzymes as c-MAF inhibitory agents
- introduce ribozymes as c-MAF inhibitory agents
- introduce therapeutic methods of the invention
- describe ribozymes used in the invention
- describe inhibitory antibodies
- describe inhibitory peptides
- describe negative c-MAF dominants
- describe vectors and promoters for expressing negative c-MAF dominant variants
- describe other inhibitory compounds of c-MAF protein activity
- describe pharmaceutical compositions and administration of c-MAF inhibitory agents
- describe treatment or prevention of bone degradation in lung cancer patients with bone metastasis having elevated c-MAF levels

### Kits of the Invention

- define kits for predicting bone metastasis and determining therapy

### Method for Typing a Sample of a Subject Suffering Lung Cancer.

- outline method for typing sample and providing prognostic information

## EXAMPLES

### Example 1

- correlate c-MAF expression with clinical parameters

### Example 2

- associate c-MAF gene expression with risk of metastasis

### Example 3

- evaluate prognostic and predictive value of c-MAF for metastasis

### Example 4

- determine association of 16q22-q24 chromosome amplification with risk of metastasis

